Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829504 · ClinicalTrials.gov registry record · Phase 1
Ropinirole 0.25 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00829504: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00829504 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829504, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under fasting conditions in healthy, non-smoking, adult subjects.
Primary Outcome
Bioequivalence based on Cmax.
Interventions
- DRUG Ropinirole HCl 0.25 mg Tablets
- DRUG Requip® 0.25 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
What the finished NCT00829504 record still lists
NCT00829504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Ropinirole HCl 0.25 mg Tablets is the first listed.
NCT00829504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00829504 about?
NCT00829504 is a clinical study titled "Ropinirole 0.25 mg Tablets Under Fasting Conditions". The objective of this study was to compare the relative bioavailability of the test formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under fasting conditions in healthy, non-smokin...
What is the current status of trial NCT00829504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00829504?
The interventions under investigation include: Ropinirole HCl 0.25 mg Tablets (DRUG), Requip® 0.25 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00829504?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00829504's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia